QUANTIFICATION OF ANGIOGENESIS AS AN INDEPENDENT PREDICTOR OF PROGNOSIS IN INVASIVE BLADDER CARCINOMAS
QUANTIFICATION OF ANGIOGENESIS AS AN INDEPENDENT PREDICTOR OF PROGNOSIS IN INVASIVE BLADDER CARCINOMAS
复制标题
DOI：
10.1111/j.1464-410x.1994.tb07122.x
复制
发表时间：
1994-12-01
期刊：
影响因子：
--
通讯作者：
HARRIS, AL
中科院分区：
文献类型：
--
作者：
DICKINSON, AJ;FOX, SB;HARRIS, AL
目的探讨血管生成作为判断膀胱移行细胞癌预后的指标及其与预后的关系。材料与方法对45例膀胱移行细胞癌患者进行随访，其中G(2)T(2)例，G(3)T(2)7例，G(3)T(3)36例，男性9例，年龄50~91岁，平均年龄73个月。血管用抗血小板内皮细胞黏附分子CD31的抗体进行免疫组织化学染色。结果单因素生存分析显示，分期、分级和血管计数是影响预后的重要指标(P=0.002，P=0.007，P=0.019)。未观察到分期、分级与血管计数的关系。在根据年龄和分期调整的COX比例风险模型中，微血管密度不仅仍然是一个重要的预后指标(P=0.026)，而且在预测总体生存方面与分期一样有意义。结论微血管定量评估血管生成是浸润性膀胱癌患者生存的独立预测因子，可用于选择受益于辅助治疗的患者。
Objective To evaluate angiogenesis as a prognostic marker of transitional cell carcinoma of the bladder and to assess its relationship to established variables for survival.Materials and methods Forty-five tumours (two G(2)T(2), seven G(3)T(2) and 36 G(3)T(3)) from 36 men and nine women with a mean age of 73 years (range 50-91), who had been followed-up for a median of 37 months (range 1-50), were examined. Vessels were immunohistochemically highlighted using an antibody to the platelet endothelial cell adhesion molecule, CD31. Microvessel density was quantified using a Chalkley point eyepiece graticule.Results Univariate analysis of survival showed stage, grade and vascular count were significant indicators of prognosis (P=0.002, P=0.007, P=0.019 respectively). No relationship was observed between stage and grade and vascular count. In a Cox proportional hazard model, adjusted for age and stage, microvessel density not only remained a significant prognostic indicator (P=0.026) but was as informative as stage in predicting overall survival. A high vascular count conferred a 2.5 increased risk of mortality.Conclusions These findings suggest that assessment of angiogenesis by microvessel quantification is an independent predictor of survival in patients with invasive bladder carcinoma and might be useful in selecting those who would benefit from adjuvant therapy.